person · Reporting owner

Kazam Joshua A

Disclosed activity across 11 companies

Tapewire entity: 35936
SEC CIK: 0001221355

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allogene Therapeutics, Inc.ALLO · Entity 5243	Director	June 18, 2026	June 23, 2026
CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337	Director	December 31, 2017	February 14, 2018
DraftKings Holdings Inc.DEAC · Entity 127463	Director	December 31, 2019	December 31, 2019
Firy Inc.FEAC · Entity 6462	Director	March 05, 2020	March 05, 2020
Ginkgo Bioworks Holdings, Inc.SRNG · Entity 5530	Director	February 23, 2021	February 24, 2021
Screaming Eagle Acquisition Corp.SCRM · Entity 91822	Director	January 05, 2022	January 06, 2022
Target Hospitality Corp.EAGL · Entity 4584	Director	March 05, 2019	March 05, 2019
Tishman Speyer Innovation Corp. IITSIB · Entity 140810	Director	February 12, 2021	February 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allogene Therapeutics, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	398,463	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 47,700 · Balance 398,463
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Exercise / conversion · Disposed 47,700 · Balance 0 F1: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan. F2: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	95,400	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F2: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan.

F2: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

CAPRICOR THERAPEUTICS, INC.

Report date December 31, 2017 · Filed February 14, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,298	Ending reported balance After 2017-12-27 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-12-26 · Gift · Disposed 1,000 · Balance 37,084 F1: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Row 2 · 2017-12-27 · Gift · Disposed 17,786 · Balance 19,298 F1: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust.
Common StockSEC Table I · non-derivative	IndirectBy Kazam Family Trust	12,276	Reported balance Holding disclosure · report date 2017-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,276
Common StockSEC Table I · non-derivative	IndirectBy Spouse for Minor Child	3,310	Reported balance Holding disclosure · report date 2017-12-31 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 3,310 F2: Held by the Reporting Person's spouse as custodian for the benefit of their minor child under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purpose. F3: The Reporting Person previously reported, in a Form 4 filed with the Securities and Exchange Commission on January 22, 2015, indirect beneficial ownership of 3,310 shares of Common Stock held by the Kash Family Foundation, of which the Reporting Person was at the time a co-trustee with the ability to vote and dispose of the shares. The Reporting Person had no pecuniary interest in the shares held by the Foundation. Subsequent to January 22, 2015, the Reporting Person ceased to serve as a co-trustee of the Foundation and accordingly the shares held by the Foundation are not reported in this Form 5.

Filing footnotes · ownership attribution and instrument terms

F1: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust.

F2: Held by the Reporting Person's spouse as custodian for the benefit of their minor child under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

F3: The Reporting Person previously reported, in a Form 4 filed with the Securities and Exchange Commission on January 22, 2015, indirect beneficial ownership of 3,310 shares of Common Stock held by the Kash Family Foundation, of which the Reporting Person was at the time a co-trustee with the ability to vote and dispose of the shares. The Reporting Person had no pecuniary interest in the shares held by the Foundation. Subsequent to January 22, 2015, the Reporting Person ceased to serve as a co-trustee of the Foundation and accordingly the shares held by the Foundation are not reported in this Form 5.

DraftKings Holdings Inc.

Report date December 31, 2019 · Filed December 31, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table II · derivative / convertible security	Direct	20,000	Reported balance After 2019-12-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-31 · Other · Acquired 20,000 · Balance 20,000 F1: On December 31, 2019, Eagle Equity Partners, LLC, the sponsor of the Issuer (the "Sponsor"), transferred 20,000 shares of Class B common stock of the Issuer to each of the Issuer's independent directors at a price per share equal to par value. The Reporting Person is an independent director of the Issuer. F2: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-230815) (the "Registration Statement") and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: On December 31, 2019, Eagle Equity Partners, LLC, the sponsor of the Issuer (the "Sponsor"), transferred 20,000 shares of Class B common stock of the Issuer to each of the Issuer's independent directors at a price per share equal to par value. The Reporting Person is an independent director of the Issuer.

F2: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-230815) (the "Registration Statement") and have no expiration date.

Firy Inc.

Report date March 05, 2020 · Filed March 05, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Common StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-03-05 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-236367) (the "Registration Statement") and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-236367) (the "Registration Statement") and have no expiration date.

Ginkgo Bioworks Holdings, Inc.

Report date February 23, 2021 · Filed February 24, 2021

This filing explicitly reported no securities owned.

Screaming Eagle Acquisition Corp.

Report date January 05, 2022 · Filed January 06, 2022

This filing explicitly reported no securities owned.

Target Hospitality Corp.

Report date March 05, 2019 · Filed March 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	10,000	Reported balance After 2019-03-05 transaction · row 1 1 source row Row 1 · 2019-03-05 · Purchase · Acquired 5,000 · Balance 10,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.185 to $10.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.185 to $10.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Tishman Speyer Innovation Corp. II

Report date February 12, 2021 · Filed February 16, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	25,000	Reported balance After 2021-02-12 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-02-12 · Purchase · Acquired 25,000 · Balance 25,000 F1: The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the "Issuer") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant.
Redeemable warrantsSEC Table II · derivative / convertible security	Direct	5,000	Reported balance After 2021-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-12 · Purchase · Acquired 5,000 · Balance 5,000 F1: The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the "Issuer") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant. F2: Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The warrants will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering. The warrants will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation, as described under the heading "Description of Securities-Redeemable Warrants-Public Stockholders' Warrants" in the Issuer's registration statement on Form S-1 (File No. 333-252423).

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the "Issuer") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant.

F2: Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The warrants will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering. The warrants will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation, as described under the heading "Description of Securities-Redeemable Warrants-Public Stockholders' Warrants" in the Issuer's registration statement on Form S-1 (File No. 333-252423).

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kite Pharma, Inc.

Report date September 28, 2017 · Filed October 06, 2017

Section 16 reporting ended · disclosed 2017-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy spouse	70,050	Reported balance After 2017-09-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-09-28 · Other · Acquired 70,050 · Balance 70,050 F1: The shares were transferred from an irrevocable blind grantor trust, which is managed by an independent trustee, for no consideration. The Reporting Person holds no voting or dispositive power over the securities held by the trust.
Common StockSEC Table I · non-derivative	IndirectBy spouse	0	Reported balance After 2017-10-03 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-10-03 · Disposition to issuer · Disposed 70,050 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2017-10-03 transaction · row 4 2 source rows · reconciled sequence Row 3 · 2017-10-03 · Other · Disposed 2,553 · Balance 1,807 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Row 4 · 2017-10-03 · Disposition to issuer · Disposed 1,807 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F4: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2024-03-24	Direct	0	Reported balance After 2017-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-10-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F5: This option provided for vesting of 1/36th of the shares subject thereto on February 28, 2014, and for vesting of the remaining shares subject thereto in 35 equal monthly installments commencing March 30, 2014.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.23 · Expires 2025-06-08	Direct	0	Reported balance After 2017-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7: This option provided for vesting in 12 equal monthly installments following June 9, 2015.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.87 · Expires 2026-05-31	Direct	0	Reported balance After 2017-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-10-03 · Disposition to issuer · Disposed 7,000 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F8: This option provided for vesting in 12 equal monthly installments following June 1, 2016.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.21 · Expires 2027-06-19	Direct	0	Reported balance After 2017-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-10-03 · Disposition to issuer · Disposed 8,810 · Balance 0 F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F9: This option provided for vesting in 12 equal monthly installments following June 20, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were transferred from an irrevocable blind grantor trust, which is managed by an independent trustee, for no consideration. The Reporting Person holds no voting or dispositive power over the securities held by the trust.

F2: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes.

F3: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.

F4: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.

F5: This option provided for vesting of 1/36th of the shares subject thereto on February 28, 2014, and for vesting of the remaining shares subject thereto in 35 equal monthly installments commencing March 30, 2014.

F6: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option.

F7: This option provided for vesting in 12 equal monthly installments following June 9, 2015.

F8: This option provided for vesting in 12 equal monthly installments following June 1, 2016.

F9: This option provided for vesting in 12 equal monthly installments following June 20, 2017.

Kronos Bio, Inc.

Report date June 20, 2025 · Filed June 20, 2025

Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-06-20 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-06-20 · Other · Disposed 94,481 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: 68,815 of the shares are held jointly with spouse.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2031-06-21	Direct	Reported balance After 2025-06-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-20 · Disposition to issuer · Disposed 20,600 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21	Direct	Reported balance After 2025-06-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21	Direct	Reported balance After 2025-06-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24	Direct	Reported balance After 2025-06-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: 68,815 of the shares are held jointly with spouse.

F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Latch, Inc.

Report date June 04, 2021 · Filed June 07, 2021

Section 16 reporting ended · disclosed 2021-06-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	30,000	Reported balance After 2021-06-04 transaction · row 1 1 source row Row 1 · 2021-06-04 · Exercise / conversion · Acquired 30,000 · Balance 30,000 F2: On June 4, 2021, TS Innovation Acquisitions Corp. ("TSIA" and the former name of the Issuer) consummated the Business Combination with Latch, Inc. In connection with the Business Combination, each Class B share converted to one Class A share. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination. F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the "Business Combination"), on a one-for-one basis.
Class B common stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-04 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the "Business Combination"), on a one-for-one basis. F2: On June 4, 2021, TS Innovation Acquisitions Corp. ("TSIA" and the former name of the Issuer) consummated the Business Combination with Latch, Inc. In connection with the Business Combination, each Class B share converted to one Class A share. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the "Business Combination"), on a one-for-one basis.

F2: On June 4, 2021, TS Innovation Acquisitions Corp. ("TSIA" and the former name of the Issuer) consummated the Business Combination with Latch, Inc. In connection with the Business Combination, each Class B share converted to one Class A share. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 15, 2018 Filed Oct 17, 2018 21:31 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionCommon Stock	18,716	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-055379 · doc4.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document
January 17, 2018 Filed Jan 19, 2018 00:10 UTC	Target Hospitality Corp. EAGL · Entity 4584	GrantPrivate Placement Warrants · Derivative	333,334	$1.50 Strike: $11.50	$500,001.00	Disclosure SEC source: 0001144204-18-002700 · tv483606_form4.xml · derivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,334 Underlying: Class A Ordinary Shares · 333,334 shares Expires not disclosed F1 · derivative.exercise_price: Each Private Placement Warrant ("PPW") is exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment as described under the headings "Description of Securities-Warrants-Private Placement Warrants" and "Description of Securities-Warrants-Private Placement Warrants" in the Issuer's registration statement on Form S-1 (File No. 333-222279). F2 · derivative.exercise_date: The PPWs become exercisable beginning on the later of January 17, 2019 or 30 days after the completion of the Issuer's initial business combination as described under the headings "Description of Securities-Warrants-Private Placement Warrants" and "Description of Securities-Warrants-Private Placement Warrants" in the Issuer's registration statement on Form S-1 (File No. 333-222279). F3 · derivative.expiration_date: The PPWs will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation as described under the headings "Description of Securities--Warrants-Private Placement Warrants" and "Description of Securities--Warrants-Private Placement Warrants" in the Issuer's registration statement on Form S-1 (File No. 333-222279). Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:03 UTC	CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $1.57	$0.00	Disclosure SEC source: 0001144204-18-000861 · tv482718_4.xml · derivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: 10,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 7,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document
December 27, 2017 Filed Feb 14, 2018 22:16 UTC	CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337	GiftCommon Stock	17,786	$0.00	$0.00	Disclosure SEC source: 0001144204-18-009043 · tv485800_5.xml · nonDerivative · entry 2 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,298 F1 · kind: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document
December 26, 2017 Filed Feb 14, 2018 22:16 UTC	CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337	GiftCommon Stock	1,000	$0.00	$0.00	Disclosure SEC source: 0001144204-18-009043 · tv485800_5.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,084 F1 · kind: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	8,810	$88.79 Strike: $91.21	$782,239.90	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · derivative · entry 8 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F9 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 20, 2017. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	7,000	$129.13 Strike: $50.87	$903,910.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · derivative · entry 7 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-31 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F8 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 1, 2016. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	10,000	$120.77 Strike: $59.23	$1,207,700.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · derivative · entry 6 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-08 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7 · derivative.exercise_date: This option provided for vesting in 12 equal monthly installments following June 9, 2015. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	50,000	$178.65 Strike: $1.35	$8,932,500.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · derivative · entry 5 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-03-24 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6 · price: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F5 · derivative.exercise_date: This option provided for vesting of 1/36th of the shares subject thereto on February 28, 2014, and for vesting of the remaining shares subject thereto in 35 equal monthly installments commencing March 30, 2014. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	1,807	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · nonDerivative · entry 4 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F4 · price: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	OtherCommon Stock	2,553	$180.00	$459,540.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · nonDerivative · entry 3 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,807 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	70,050	$180.00	$12,609,000.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · nonDerivative · entry 2 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F3 · date: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Read SEC document
September 28, 2017 Filed Oct 6, 2017 00:25 UTC	Kite Pharma, Inc. KITE · Entity 172664	OtherCommon Stock	70,050	$0.00	$0.00	Disclosure SEC source: 0001209191-17-056236 · doc4.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 70,050 F1 · kind: The shares were transferred from an irrevocable blind grantor trust, which is managed by an independent trustee, for no consideration. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document
June 20, 2017 Filed Jun 22, 2017 18:38 UTC	Kite Pharma, Inc. KITE · Entity 172664	GrantDirector Stock Option (Right to Buy) · Derivative	8,810	$0.00 Strike: $91.21	$0.00	Disclosure SEC source: 0001209191-17-041305 · doc4.xml · derivative · entry 2 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 Underlying: Common Stock · 8,810 shares Expires 2027-06-19 F1 · derivative.exercise_date: The stock option shall vest in 12 successive equal monthly installments following the date of grant. Read SEC document
June 20, 2017 Filed Jun 22, 2017 18:38 UTC	Kite Pharma, Inc. KITE · Entity 172664	GrantCommon Stock	2,410	$0.00	$0.00	Disclosure SEC source: 0001209191-17-041305 · doc4.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,360 Read SEC document
January 03, 2017 Filed Jan 5, 2017 02:44 UTC	CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337	GrantStock Option (right to buy) · Derivative	16,060	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001144204-17-000704 · v456180_4.xml · derivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,060 Underlying: Common Stock · 16,060 shares Expires 2027-01-03 F1 · derivative.exercise_date: 8,560 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 7,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document
September 28, 2016 Filed Feb 14, 2017 23:17 UTC	Kite Pharma, Inc. KITE · Entity 172664	GiftCommon Stock	215,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-010786 · doc5.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950 F1 · kind: Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.